Mo-Rez

Preclinical

GSK

Mo-Rez is one of 3 therapeutic programs targeting Tumours, Gynecological. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Tumours, GynecologicalRecruiting

Tumours, GynecologicalPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Tumours, Gynecological

#DrugCompanyPhaseTrials

Dostarlimab

Incyte

Preclinical

1 2

Avastin

BBio-Thera Solutions

Preclinical

1 3

Mo-Rez

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Tumours, Gynecological

NCT06796907

Clinical

Trials by Indication[1]

Tumours, Gynecological1 trial

A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Recruiting· GSK logo

GSK·Preclinical·NCT06796907·305 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mo-Rez. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mo-Rez. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: GSK

Mo-Rez

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Tumours, Gynecological1 trial

References

Drug Info

Quick Facts

Related News